Mopidralazine

Mopidralazine

SCHEMBL2109925

Cc1ccc(C)n1Nc1ccc(N2CCOCC2)nn1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.53
▸ PKM P14618 1/20 0.53
▸ ALDH1A1 P00352 5/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ HTT P42858 3/20 0.52
▸ CNR2 P34972 7/20 0.48
▸ MAPT P10636 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11166349 0.86 CYP1A2 (0.45) KDM4EPKMALDH1A1SMN1; SMN2HTT
SCHEMBL11169262 0.85 CYP1A2 (0.47) KDM4EPKMSMN1; SMN2HTTCNR2
SCHEMBL11163911 0.84 KDM4E (0.42) KDM4EPKMALDH1A1SMN1; SMN2MAPT
SCHEMBL11162271 0.82 BPTF (0.60) KDM4EALDH1A1HTTHSD17B10TDP1
SCHEMBL11167255 0.82 BPTF (0.41) KDM4EPKMALDH1A1SMN1; SMN2HTT
SCHEMBL11171300 0.82 KDM4E (0.47) KDM4EPKMALDH1A1SMN1; SMN2HTT
SCHEMBL16840723 0.80 KDM4E (0.56) KDM4EPKMALDH1A1SMN1; SMN2HTT
SCHEMBL11298447 0.78 KDM4E (0.54) KDM4EPKMALDH1A1SMN1; SMN2HTT
SCHEMBL5754979 0.77 ALDH1A1 (0.61) KDM4EPKMALDH1A1SMN1; SMN2HTT
SCHEMBL10970673 0.76 KDM4E (0.56) KDM4EPKMALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-0054816-B1 PROCESS FOR PREPARING N-PYRROLYL-PYRIDAZINEAMINE DERIVATIVES GRUPPO LEPETIT S.P.A. (IT) 1985-08-07 — — EP claimed
US-4385179-A Process for preparing N-pyrrolyl-pyridazineamine derivatives GRUPPO LEPETIT S.P.A. (IT) 1983-05-24 — — US claimed
EP-0009655-B1 6-AMINO SUBSTITUTED N-PYRROLYL-3-PYRIDAZINE AMINES, THEIR PREPARATION, AND PHARMACEUTICALLY ANTIHYPERTENSIVE COMPOSITIONS CONTAINING THEM GRUPPO LEPETIT S.P.A. (IT) 1983-05-11 — — EP claimed
EP-0054816-A1 Process for preparing N-pyrrolyl-pyridazineamine derivatives GRUPPO LEPETIT S.P.A. (IT) 1982-06-30 — — EP claimed
US-4247551-A N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents GRUPPO LEPETIT S.P.A. (IT) 1981-01-27 — — US claimed
EP-0009655-A1 6-Amino substituted N-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them GRUPPO LEPETIT S.P.A. (IT) 1980-04-16 — — EP claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 — — US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 — — US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 — — US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US disclosed
EP-0009655-B1 6-AMINO SUBSTITUTED N-PYRROLYL-3-PYRIDAZINE AMINES, THEIR PREPARATION, AND PHARMACEUTICALLY ANTIHYPERTENSIVE COMPOSITIONS CONTAINING THEM GRUPPO LEPETIT S.P.A. (IT) 1983-05-11 — — EP disclosed
EP-0054816-A1 Process for preparing N-pyrrolyl-pyridazineamine derivatives GRUPPO LEPETIT S.P.A. (IT) 1982-06-30 — — EP disclosed
US-4247551-A N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents GRUPPO LEPETIT S.P.A. (IT) 1981-01-27 — — US disclosed
EP-0009655-A1 6-Amino substituted N-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them GRUPPO LEPETIT S.P.A. (IT) 1980-04-16 — — EP disclosed
Send feedback